ALK: a tyrosine kinase target for cancer therapy

@inproceedings{Holla2017ALKAT,
  title={ALK: a tyrosine kinase target for cancer therapy},
  author={Vijaykumar R. Holla and Yasir Y. Elamin and Ann M. Bailey and Amber M. Johnson and Beate Litzenburger and Yekaterina Khotskaya and Nora S. Sanchez and Jia Zeng and Md Abu Shufean and Kenna R. Mills Shaw and John Mendelsohn and Gordon B. Mills and Funda Meric-Bernstam and George Rajan Simon},
  booktitle={Cold Spring Harbor molecular case studies},
  year={2017}
}
The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL). Most prevalent ALK alterations are chromosomal rearrangements resulting in fusion genes, as seen in ALCL and NSCLC. In other tumors, ALK copy-number gains and activating ALK mutations have been described. Dramatic and often prolonged… CONTINUE READING
Highly Cited
This paper has 461 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
8 Citations
173 References
Similar Papers

Citations

Publications citing this paper.

461 Citations

0500100020172018
Citations per Year
Semantic Scholar estimates that this publication has 461 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 173 references

Similar Papers

Loading similar papers…